investorscraft@gmail.com

Stock Analysis & ValuationLiminatus Pharma, Inc. Class A Common Stock (LIMN)

Previous Close
$0.55
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

6 Centerpointe Drive
La Palma, CA 90623
United States
Industry: Biotechnology
Sector: Healthcare
CEO: Chris Kim
Full Time Employees: 3

Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.

HomeMenuAccount